<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397617</url>
  </required_header>
  <id_info>
    <org_study_id>T-117</org_study_id>
    <nct_id>NCT01397617</nct_id>
  </id_info>
  <brief_title>Randomized, Open Investigation Evaluating the Efficacy of Nobel Biocare SFB and CFB Implants</brief_title>
  <official_title>Evaluation of NobelBiocare SFB and CFB Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobel Biocare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobel Biocare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the survival rate, marginal bone resorption, soft
      tissue health and maintenance of the NobelActive Internal and External implants and to make
      comparisons with the NobelReplace Tapered Groovy implant placed in healed sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine safety and efficacy parameters for the NobelActive
      Internal and External implants and to make comparisons with the NobelReplace Tapered Groovy
      implant placed in healed sites.

      Safety: AEs

      Efficacy:

        -  survival rates,

        -  marginal bone resorption with marginal bone levels measurement,

        -  soft tissue health and maintenance via gingival index measurement, plaque index, papilla
           index .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint Was the Change in Marginal Bone Levels (in mm) From the Time of Implant Insertion to Follow-up Visits (3,6,12,24,36 and 60 Months).</measure>
    <time_frame>baseline, 3 months, 6 months, 12 months, 24 months, 36 months and 60 months</time_frame>
    <description>Marginal bone remodeling is calculated for each side of the implant (mesial and distal) separately, as the difference between bone levels at two time points. The average of mesial and distal remodeling is then calculated for each implant site (paired for each side between two different points). Negative numbers indicate bone loss. Implant insertion was defined as a baseline.
Missing data was not imputed and not included in evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant Survival Rate From the Time of Implant Insertion to Follow-up Visits (3,6,12,24,36 and 60 Months).</measure>
    <time_frame>baseline, 3 months, 6 months, 12 months, 24 months, 36 months and 60 months</time_frame>
    <description>An implant was reported to be a surviving implant when it remained in the jaw and was functionally loaded even if not all the individual success criteria were fulfilled (i) an implant that causes no allergic, toxic or gross infectious reactions either locally or systemically, ii) offered anchorage to a functional prosthesis, iii) showed no signs of fracture or bending, iv) showed no signs of peri-implant radiolucency on an intraoral radiograph using a paralleling technique strictly perpendicular to the implant-bone interface, and v) showed no mobility when individually tested by either tapping or rocking with a hand instrument).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Partial Edentulism</condition>
  <condition>Complete Edentulism</condition>
  <arm_group>
    <arm_group_label>NobelActive Internal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NobelActive Internal implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NobelActive External</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NobelActive External implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NobelReplace Tapered Groovy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NobelReplace Tapered Groovy implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NobelActive Internal implant</intervention_name>
    <description>Dental implant</description>
    <arm_group_label>NobelActive Internal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NobelActive External implant</intervention_name>
    <description>Dental implant</description>
    <arm_group_label>NobelActive External</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NobelReplace Tapered Groovy implant</intervention_name>
    <description>Dental implant</description>
    <arm_group_label>NobelReplace Tapered Groovy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject should be in need of an implant supported fixed restoration

          -  The subjects should have sufficient bone volume and density i.e. an osseous
             architecture in the planned implant placement region sufficient to receive implants
             with a diameter of 3.5 mm and a length of at least 10 mm.

          -  The subject as well as the implant sites should fulfill criteria for immediate
             functional tem-porization within 24 h.

          -  The implant sites should be healed and free from infection.

        Exclusion Criteria:

          -  Alcohol or drug abuse as noted in patient records or in patient history.

          -  Health conditions, which do not permit the surgical procedure.

          -  Reason to believe that the treatment might have a negative effect on the subject's
             total situation (psychiatric problems), as noted in patient records or in patient
             history.

          -  The subject is not able to give her/his informed consent to participate.

          -  The need of bone augmentation before implant installation to obtain a prosthetically
             correct implantation transversally. However, a minor augmentation procedure to cover
             exposed threads or interproximal / buccal grafting due to deficient sites is not an
             exclusion criteria.

          -  Any disorders in the planned implant area such as previous tumors, chronic bone
             disease, or previous irradiation.

          -  Uncontrolled diabetics will be excluded.

          -  Severe bruxism or other destructive habits.

          -  Immediate insertion (e.g. placement of the implant immediately after extraction)
             consti-tutes an exclusion criterion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <results_first_submitted>December 8, 2015</results_first_submitted>
  <results_first_submitted_qc>March 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2016</results_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NobelActive Internal</title>
          <description>NobelActive Internal implant
NobelActive Internal implant</description>
        </group>
        <group group_id="P2">
          <title>NobelActive External</title>
          <description>NobelActive External implant
NobelActive External implant</description>
        </group>
        <group group_id="P3">
          <title>NobelReplace Tapered Groovy</title>
          <description>NobelReplace Tapered Groovy implant
NobelReplace Tapered Groovy implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NobelActive Internal</title>
          <description>NobelActive Internal implant
NobelActive Internal implant</description>
        </group>
        <group group_id="B2">
          <title>NobelActive External</title>
          <description>NobelActive External implant
NobelActive External implant</description>
        </group>
        <group group_id="B3">
          <title>NobelReplace Tapered Groovy</title>
          <description>NobelReplace Tapered Groovy implant
NobelReplace Tapered Groovy implant</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="13.1"/>
                    <measurement group_id="B2" value="49.9" spread="13.6"/>
                    <measurement group_id="B3" value="46.9" spread="14.6"/>
                    <measurement group_id="B4" value="48.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint Was the Change in Marginal Bone Levels (in mm) From the Time of Implant Insertion to Follow-up Visits (3,6,12,24,36 and 60 Months).</title>
        <description>Marginal bone remodeling is calculated for each side of the implant (mesial and distal) separately, as the difference between bone levels at two time points. The average of mesial and distal remodeling is then calculated for each implant site (paired for each side between two different points). Negative numbers indicate bone loss. Implant insertion was defined as a baseline.
Missing data was not imputed and not included in evaluation.</description>
        <time_frame>baseline, 3 months, 6 months, 12 months, 24 months, 36 months and 60 months</time_frame>
        <population>Intent to treat analysis (all participants who received at least one implant were analyzed). Missing data was not imputed and not included in evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>NobelActive External</title>
            <description>NobelActive External implant
NobelActive External implant</description>
          </group>
          <group group_id="O2">
            <title>NobelActive Internal</title>
            <description>NobelActive Internal implant
NobelActive Internal implant</description>
          </group>
          <group group_id="O3">
            <title>NobelReplace Tapered Groovy</title>
            <description>NobelReplace Tapered Groovy implant
NobelReplace Tapered Groovy implant</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint Was the Change in Marginal Bone Levels (in mm) From the Time of Implant Insertion to Follow-up Visits (3,6,12,24,36 and 60 Months).</title>
          <description>Marginal bone remodeling is calculated for each side of the implant (mesial and distal) separately, as the difference between bone levels at two time points. The average of mesial and distal remodeling is then calculated for each implant site (paired for each side between two different points). Negative numbers indicate bone loss. Implant insertion was defined as a baseline.
Missing data was not imputed and not included in evaluation.</description>
          <population>Intent to treat analysis (all participants who received at least one implant were analyzed). Missing data was not imputed and not included in evaluation.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>implant insertion to 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="1.50"/>
                    <measurement group_id="O2" value="-0.98" spread="1.60"/>
                    <measurement group_id="O3" value="-1.13" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="1.06"/>
                    <measurement group_id="O2" value="-0.89" spread="1.65"/>
                    <measurement group_id="O3" value="-0.85" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.83"/>
                    <measurement group_id="O2" value="-0.68" spread="1.35"/>
                    <measurement group_id="O3" value="-0.96" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.97"/>
                    <measurement group_id="O2" value="-0.95" spread="1.37"/>
                    <measurement group_id="O3" value="-0.63" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.96"/>
                    <measurement group_id="O2" value="-1.03" spread="1.36"/>
                    <measurement group_id="O3" value="-0.75" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="1.03"/>
                    <measurement group_id="O2" value="-0.96" spread="1.15"/>
                    <measurement group_id="O3" value="-0.86" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Survival Rate From the Time of Implant Insertion to Follow-up Visits (3,6,12,24,36 and 60 Months).</title>
        <description>An implant was reported to be a surviving implant when it remained in the jaw and was functionally loaded even if not all the individual success criteria were fulfilled (i) an implant that causes no allergic, toxic or gross infectious reactions either locally or systemically, ii) offered anchorage to a functional prosthesis, iii) showed no signs of fracture or bending, iv) showed no signs of peri-implant radiolucency on an intraoral radiograph using a paralleling technique strictly perpendicular to the implant-bone interface, and v) showed no mobility when individually tested by either tapping or rocking with a hand instrument).</description>
        <time_frame>baseline, 3 months, 6 months, 12 months, 24 months, 36 months and 60 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>NobelActive Internal</title>
            <description>NobelActive Internal implant
NobelActive Internal implant: Dental implant</description>
          </group>
          <group group_id="O2">
            <title>NobelActive External</title>
            <description>NobelActive External implant
NobelActive External implant: Dental implant</description>
          </group>
          <group group_id="O3">
            <title>NobelReplace Tapered Groovy</title>
            <description>NobelReplace Tapered Groovy implant
NobelReplace Tapered Groovy implant: Dental implant</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival Rate From the Time of Implant Insertion to Follow-up Visits (3,6,12,24,36 and 60 Months).</title>
          <description>An implant was reported to be a surviving implant when it remained in the jaw and was functionally loaded even if not all the individual success criteria were fulfilled (i) an implant that causes no allergic, toxic or gross infectious reactions either locally or systemically, ii) offered anchorage to a functional prosthesis, iii) showed no signs of fracture or bending, iv) showed no signs of peri-implant radiolucency on an intraoral radiograph using a paralleling technique strictly perpendicular to the implant-bone interface, and v) showed no mobility when individually tested by either tapping or rocking with a hand instrument).</description>
          <population>Intention to treat analysis.</population>
          <units>percentage of surviving implants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                    <measurement group_id="O2" value="97.6"/>
                    <measurement group_id="O3" value="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded during the duration of the study with the 5-year follow up.</time_frame>
      <desc>From implant insertion to 5 years follow-up 31 patient was lost to follow-up in NobelActive External group, 31 patient was lost to follow-up in NobelActive Internal group and 29 patient was lost to follow-up in NobelReplace group.</desc>
      <group_list>
        <group group_id="E1">
          <title>NobelActive External</title>
          <description>NobelActive External implant
NobelActive External implant</description>
        </group>
        <group group_id="E2">
          <title>NobelActive Internal</title>
          <description>NobelActive Internal implant
NobelActive Internal implant</description>
        </group>
        <group group_id="E3">
          <title>NobelReplace Tapered Groovy</title>
          <description>NobelReplace Tapered Groovy implant
NobelReplace Tapered Groovy implant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>cardiac valve surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>squamous cell cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hypesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head Clinical Trial Management</name_or_title>
      <organization>Nobel Biocare Services AG</organization>
      <phone>+41 43 211 42 00</phone>
      <email>isabelle.arrighi@nobelbiocare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

